Leukocyte-platelet Rich Fibrin for Alveolar Ridge Preservation (L-PRF)

January 3, 2023 updated by: Antonio Sanz, Universidad de los Andes, Chile

Autologous Leukocyte-platelet Rich Fibrin (L-PRF) Versus a Xenogeneic Bone Substitute Combined With a Collagen Matrix for Alveolar Ridge Preservation. A Randomized Controlled Clinical Trial

After tooth extraction, there is a subsequent bone loss as a part of the natural healing of the tissue. Up to 50% of bone loss occurs during the first three months after extraction, jeopardizing a possible implant treatment. Alveolar ridge preservation techniques reduce bone loss, allowing a future implant treatment. Different bone filling materials have been used with good clinical results. The second-generation platelet concentrates (L-PRF) have recently been shown to induce bone regeneration when filling the socket after extraction, with significant biological and economic advantages. The hypothesis of this study is to test whether or not the use of L-PRF in alveolar ridge preservation results in a non-inferior horizontal radiographic change compared with the combination of a xenogeneic bone substitute with a collagen matrix.

Study Overview

Detailed Description

This study is a non inferiority clinical controlled trial of parallel groups. Study Intervention and Indication

After single premolar extractions in the maxilla or mandible area, patients will be randomly allocated to either one of the two treatment modalities:

  • Alveolar ridge preservation using L-PRF (test)
  • Alveolar ridge preservation using xenogeneic bone covered with a collagen matrix (control)

Study objectives Primary Objective The present study aims to test whether or not the use of L-PRF in alveolar ridge preservation results in non-inferior horizontal ridge width changes measured at - 1 mm below the most coronal aspect of the alveolar crest compared to the combination of a xenogeneic bone substitute material with a collagen matrix, 4 months after tooth extraction.

Clinical procedures

Extraction surgery

Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included. All surgical procedures will be performed under local anesthesia. After disinfection of the surgical site with 0.2% chlorhexidine solution (PerioAid® Treatment, Barcelona, Spain), local anesthetics (Lidocaine HCl 2% with epinephrine 1:100,000; XXX) will be administered by infiltration at the respective buccal and lingual sites at maxilla or inferior alveolar nerve block technique on the mandible. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap. After that, patients will be randomly assigned to either one of the two treatment modalities:

  • Alveolar ridge preservation with leukocyte-platelet rich fibrin (L-PRF) (test)
  • Alveolar ridge preservation using xenogeneic bone covered with a collagen matrix (DBBM+CM) (control)

Clinical procedures A venepuncture will be performed before any surgery (irrespective of the later randomization). Six plastic sterile 9 mL tubes without anticoagulant will be drawn with venous blood from the median basilica vein, median cubital vein, or median cephalic vein. Preparation of the L-PRF clots and membranes will be performed as previously described. In brief, within 60 seconds after the blood draws, the tubes will be centrifuged at 408 g RCF for 12 min using a tabletop centrifuge (IntraSpinTM, IntraLock®, Florida, USA). Following centrifugation, L-PRF clots will be removed from the tube, separated from the remaining red thrombus at the base with tweezers, and gently compressed into membranes using a metal rack and a metal plate.

Extraction surgery

Partially edentulous patients needing a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. All surgical procedures will be performed under local anesthesia. After disinfection of the surgical site with 0.2% chlorhexidine solution (PerioAid® Treatment, Barcelona, Spain), local anesthetics (Lidocaine HCl 2% with epinephrine 1:100,000; XXX) will be administered by infiltration at the respective buccal and lingual sites at maxilla or inferior alveolar nerve block technique on the mandible. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap. After that, patients will be randomly assigned to either one of the two treatment modalities:

  • Alveolar ridge preservation with leukocyte-platelet rich fibrin (L-PRF) (test)
  • Alveolar ridge preservation using xenogeneic bone covered with a collagen matrix (DBBM+CM) (control)

In group L-PRF group, 2-5 PRF clots, depending on the size of the socket, will be inserted and compressed with a large plunger until they reach the alveolar crest as previously described (Temmerman et al., 2016). The site will thereafter be covered with 2-3 L-PRF membranes. Then, crossed horizontal mattress suture will be placed, followed by single interrupted sutures for better stabilization (Vicryl 4.0 EthiconTM, Johnsson & Johnsson, New Jersey, New York, USA). No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.

In group DBBM+CM, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures (Vicryl 4.0 EthiconTM, Johnsson & Johnsson, New Jersey, New York, USA) will be placed to stabilize the collagen matrix. Sutures will be removed within 7-10 days. The grafted socket will then be left to heal for 4 months.

The xenogenic material DBBM will be Bio-Oss Collagen®, and collagen matrix Bio-Gide® both delivered as the Combi-Kit Collagen (Geistlich Pharma AG - Switzerland).

Immediately after surgery, despite the treatment group, the patient will be scanned using a CBCT (cone beam computed tomography)

Implant surgery

At 4 months, patients from both groups will be recalled for implant placement. Before the surgery, a CBCT and an impression will be taken. Moreover, clinical data will be recorded. Upon local anesthesia, a full flap will be raised, and a biopsy will be taken in the center of the implant site using a trephine drill (inner diameter 2mm). Thereafter, the implant will be placed according to the manufacturer's recommendation. A submerged healing protocol will be allowed. Final reconstructions will be inserted 4 months later.

  • Type of implants: Biohorizons 3.8 * 10.5 mm as a standard implant, inserted at bone level.
  • Healing mode: Submerged
  • No provisional reconstruction
  • Type of final reconstruction: Cad-cam screw-retained and axis screw, depending on the case.

Follow-up examinations Follow-up examinations will be performed at baseline 2 (10 days after crown insertion), 6 months, and 1 year after final restoration.

Study Type

Interventional

Enrollment (Anticipated)

38

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Region Metropolitana
      • Santiago, Region Metropolitana, Chile, 8050000
        • Recruiting
        • Centro de Salud, Universidad de los Andes
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Periodontally healthy individuals with at least 18 years of age
  2. Good oral hygiene (BOP & Pl ≤ 20%)
  3. Patients with a single failing premolar in the maxilla and mandible.
  4. With or without buccal plate after tooth extraction (similar cases in both groups)
  5. Surrounded by a mesial and distal natural tooth
  6. Capability to comply with the study procedures
  7. Informed Consent as documented by signature

Exclusion Criteria:

  1. Pregnant or lactating women
  2. Known or suspected non-compliance, drug or alcohol abuse
  3. Smokers (>10 cigarettes/day)
  4. Systemic or local conditions presenting a contraindication to implant treatment
  5. Currently taking drugs that influence bone metabolism
  6. Use of bisphosphonates in the last 4 years
  7. History of malignancy, radiotherapy or chemotherapy for malignancy in the past 5 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: L-PRF preservation (test)
Using L-PRF membranes inside the socket, covering with L-PRF membranes, (test group).

Partially edentulous patients in need of a single-tooth extraction in the premolar region[ (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with elevators and then carefully extracted with forceps without raising a flap.

L-PRF group will use 2-5 PRF clots, depending on the size of the socket, which will be inserted and compressed with a large plunger until they reach the alveolar crest. The site will thereafter be covered with L-PRF membranes. Then, crossed horizontal mattress suture will be placed followed by single interrupted sutures for stabilization. No efforts will be undertaken to obtain primary wound closure. The grafted socket will be left to heal for 4 months.

After 4 months of socket preservation, a dental implant will be inserted into the socket. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration.

Active Comparator: Xenogenic bone plus collagen membrane (control)
Bio-Oss® Collagen at the bone level and application of a collagen matrix (Combi-Kit). Both materials will be used for socket preservation (control).

Partially edentulous patients in need of a single-tooth extraction in the premolar region (maxilla or mandible), with two neighboring natural teeth, will be included in the study. The tooth will be luxated first with straight and angled elevators and then carefully extracted with forceps without raising a flap.

In the control group, the socket will be grafted with xenogeneic bone substitute material (up to the palatal/lingual bone crest) and covered with a collagen matrix. Single interrupted sutures will be placed to stabilize the collagen matrix. Sutures will be removed at 7-10 days. The grafted socket will then be left to heal for a period of 4 months.

The xenogenic material will be Bio-Oss Collagen® and collagen matrix Bio-Gide® .

After 4 months of socket preservation, a dental implant will be placed. After 4 months of implant healing, a cad cam final restoration will be delivered. The follow-up will be up to 12 months after the final restoration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bone socket horizontal and vertical changes evaluated using cbct ((cone beam computed tomography)
Time Frame: first cbct immediately after socket preservation surgery, second cbct 4 months after surgery, 12 months after the final restoration of the implant.
Cone-beam computed tomographic (CBCT) imaging will be used to assess the primary outcome (horizontal radiographic changes at -1 mm below the alveolar crest) in both groups between baseline 1 (immediately post socket preservation), visit 4 (4 months after socket preservation), and 12 months after implant rehabilitation. Linear measurements will be performed. The most apical point of the extraction socket will be defined, and two reference lines will be subsequently drawn. The vertical reference line will be drawn in the center of the extraction socket crossing the apical reference point. A horizontal reference line will be drawn perpendicular to the vertical line crossing the apical reference point. Based on these reference lines, the horizontal ridge width will then be measured at -1 mm below the alveolar crest (HW-1). The same procedure will be applied for assessing the horizontal ridge width changes will then be measured at -3 mm (HW-3) and 5- mm (HW-5) below the alveolar crest.
first cbct immediately after socket preservation surgery, second cbct 4 months after surgery, 12 months after the final restoration of the implant.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mucosal height
Time Frame: 4 months after implant insertion, at the final restoration delivery
Mucosa height measured in millimeters from the implant platform until the mucosal margin using a North Carolina periodontal probe
4 months after implant insertion, at the final restoration delivery
Peri-implant Keratinized Mucosa
Time Frame: 10 days, 6, and 12 months after final restoration
keratinized mucosal height measured in millimeters from the implant mucosal vestibular margin until the mucogingival junction using a North Carolina periodontal probe
10 days, 6, and 12 months after final restoration
Bleeding on probing
Time Frame: 10 days, 6, and 12 months after final restoration
The presence or absence (dichotomic) of bleeding around the peri-implant sulcus after a gentle probing using a North Carolina periodontal probe
10 days, 6, and 12 months after final restoration
Probing depth
Time Frame: 10 days, 6, and 12 months after final restoration
Probing depth of the peri-implant sulcus measured in millimeters at six points around de implant (3 points on the vestibular and 3 points on the lingual side) using a North Carolina periodontal probe
10 days, 6, and 12 months after final restoration
Profilometric Changes
Time Frame: at baseline (socket preservation), 4 months (implant insertion), 10 days and 12 months after final restoration delivery
Profilometric changes, measured by the digitalization of stone cast obtained from de patient. The measurements will be at 1 and 3 mm below the preoperative mucosa margin.
at baseline (socket preservation), 4 months (implant insertion), 10 days and 12 months after final restoration delivery
Phenotype
Time Frame: 10 days, 6 and 12 months after final restoration
Phenotype will be assessed by using a periodontal probe. If the probe results still visible after its insertion in the keratinized mucosa, the phenotype will be considered thin; if not, the phenotype will be classified as thick.
10 days, 6 and 12 months after final restoration
Pink esthetic score (PES)
Time Frame: 10 days, 6, and 12 months after final restoration
measured at 7 sites (mesial, distal papilla, soft tissue level, soft tissue contour, bone contour, color and texture of the soft tissue) under visual examination, using 3 scores per site (0: absence, 1: partial presence, 2: full presence) with a maximum of 14 points
10 days, 6, and 12 months after final restoration
White esthetic score (WES)
Time Frame: 10 days, 6, and 12 months after final restoration
based on tooth form, contour, color, texture, and translucence, under visual examination, using 3 scores per site (0: absence, 1: partial presence, 2: full presence) with a maximum of 14 points
10 days, 6, and 12 months after final restoration
Visual analog scale for pain assessment (VAS)
Time Frame: Pain perceived, 24 hrs after socket preservation and implant insertion (4 months).
Ten degrees of pain are used, 0 no pain, 10 the worst pain imaginable. The patient will select a degree under his perception
Pain perceived, 24 hrs after socket preservation and implant insertion (4 months).
Oral Health Impact Profile (OHIP-14)
Time Frame: at baseline, 6 and 12 months after final restoration

self-filled questionnaire that focuses on seven dimensions of impact (functional limitation, pain, psychological discomfort, physical disability, psychological disability, social disability and handicap). Patients will be asked to respond according to frequency of impact on a 5-point Likert scale coded never (score 0), hardly ever (score 1), occasionally (score2), fairly often (score 3) and very often (score 4) using a twelve-months recall period.

The OHIP-14 scores can range from 0 to 56 and are calculated by summing the ordinal values for the 14 items. Higher OHIP-14 scores indicate worse and lower scores indicate better Oral Health Related Quality of Life.

at baseline, 6 and 12 months after final restoration
Radiographic evaluation
Time Frame: 10 days, 6, and 12 months after final restoration
Intraoral calibrated X-rays images will be taken. The digitally obtained x-rays will be transferred into a software program and the pitch distance between two implant threads will be used for calibration. The marginal bone levels (MBL) will be then assessed at the mesial and distal aspects of each implant by measuring the distance between the implant shoulder and the bone crest. Thereafter, mean values will be calculated for all implants and for both groups.
10 days, 6, and 12 months after final restoration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Antonio Sanz, DDS, Professor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2022

Primary Completion (Anticipated)

October 1, 2024

Study Completion (Anticipated)

March 1, 2025

Study Registration Dates

First Submitted

May 3, 2022

First Submitted That Met QC Criteria

October 6, 2022

First Posted (Actual)

October 7, 2022

Study Record Updates

Last Update Posted (Actual)

January 5, 2023

Last Update Submitted That Met QC Criteria

January 3, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CPI-ODO:16

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alveolar Ridge Enlargement

Clinical Trials on Premolar extraction and socked preservation with L-PRF

3
Subscribe